Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer

Journal of Pathology

Volumn 219, Issue 1, 2009, Pages 1-2

  Viale, Giuseppe ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Amplification; CEP17; erbB2; HER2; Herceptin; Polysomy

Indexed keywords

LAPATINIB; TRASTUZUMAB;

BREAST CANCER; CELL COUNT; CHROMOSOME 17; COMPARATIVE GENOMIC HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MEDICAL DECISION MAKING; NOTE; NUMERICAL CHROMOSOME ABERRATION; ONCOGENE NEU; PRIORITY JOURNAL;

BREAST NEOPLASMS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PATIENT SELECTION; POLYPLOIDY; RECEPTOR, ERBB-2;

EID: 68849119063     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2593     Document Type: Note

References (13)

1. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-1333.
2. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
3. Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 2005;29:1221-1227.
4. Vanden Bempt I, van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008;26:4869-4874.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Herceptin Adjuvant (HERA) Trial Study Team: trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
7. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, 14-17 December 2006.
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. FinHer Study Investigators: adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
9. Reinholz MM, Jenkins RB, Hillman D, Lingle WL, Davidson N, Martino S, et al. The clinical significance of polysomy 17 in the HER2-N9831 intergroup adjuvant trastuzumab trial. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 13-16 December 2007 (abstr 36).
10. Marchiò C, Lambros MB, Gugliotta P, Verdun di Cantogno L, Botta C, Pasini B, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009; DOI:10.1002/path2574.
11. + and/or FISH-positive tumors: central testing results from NSABP B-31. J Clin Oncol 2007;25:5s (suppl; abstr 511).
12. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-1411.
13. Esteva FJ, Hortobagyi GN. Topoisomerase IIα amplification and anthracycline-based chemotherapy: the jury is still out. J Clin Oncol 2009;(in press).